For smaller companies with a single asset, bringing innovation to European patients can feel like an unassailable maze of country-specific requirements and slow reimbursement. NĂoSync Limited, a startup building a platform to cut through that complexity, has secured $430K in Seed funding.
The capital will support NĂoSync's efforts to provide the scale, leverage, and intelligence needed to ensure life-saving medicines reach patients across the continent, addressing a key barrier for pharmaceutical firms.
